The U.S. Naval Medical Research Center has submitted to the FDA a revised application to commence a clinical trial of Hemopure -- a stabilized hemoglobin used in the treatment of trauma patients in the battlefield. Hemopure, a product of Mass.-based firm Biopure, would eliminate the need for blood transfusions after surgery by helping patients build up their own reserves of red blood cells.

Full Story:

Related Summaries